HILE(SH:603718) Ge Long Hui A P P·2026-01-30 10:25Group 1 - The company expects to achieve a total profit of 34 million to 40 million yuan in 2025, with a net profit attributable to the parent company of 11 million to 16 million yuan, and a net profit after deducting non-recurring gains and losses of -400 million to -390 million yuan [1] - The anticipated operating revenue for 2025 is projected to be between 190 million to 195 million yuan, which is below 300 million yuan [1] - The decline in performance is primarily due to the high comparison base from the previous year, where the company realized over 100 million yuan in investment income from the sale of a 30% non-controlling stake in WuXi Vaccines [1] Group 2 - The company's subsidiary, Shaanxi Ruisheng Biotechnology Co., Ltd., is expected to experience significant performance decline starting from the second quarter of 2025 due to increased competition leading to a "price war" and tightening of previously applicable tax incentives [2] - As a result of the performance decline, the valuation based on the original acquisition's shareholder equity value is no longer reflective, leading to a supplemental agreement with the counterparty, Meilun Management Co., Ltd., to adjust the transaction price from 935 million yuan to 536 million yuan, with a return of the price difference of 399 million yuan [2]